Skip to main content

Table 1 Baseline demographic characteristics of patients enrolled in the ALZ2002 (safety set)

From: Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

Baseline characteristicsTreatment group at start ALZ2002
Placebo10 mg50 mgTotal
N393738114
Sex, men,n(%)16 (41.0)18 (48.6)20 (52.6)54 (47.4)
Age, years    
Mean (SD)70.3 (5.38)70.9 (6.58)68.1 (8.55)69.8 (6.99)
Range59; 8052; 8150; 8250; 82
Race    
White,n(%)37 (94.9)36 (97.3%)38 (100.0)111 (97.4)
Other,n(%)2 (5.1)1 (2.7)0 (0.0)3 (2.6)
APOEε4 carrier status known,n27302279
Yes,n(%)17 (63.0)18 (60.0)10 (45.5)45 (57.0)
No,n(%)10 (37.0)12 (40.0)11 (50.0)33 (41.8)
Preclinical AD, CDR = 0,n(%)7 (17.9)8 (21.6)9 (23.7)24 (21.1)
MCI due to AD, CDR = 0.5,n(%)32 (82.1)29 (78.4)29 (76.3)90 (78.9)